Fara Brasó-Maristany

19PUBLICATIONS
161CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsArt criticism
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Feb 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Apr 25, 2025
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27.

Yong Wang, Yanan Wang, Lei Bao

|Apr 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero

|Jul 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany

Pageof 4

Frequent Collaborators

15 joint publications

Aleix Prat

7 joint publications

Tomás Pascual

5 joint publications

Maria Vidal

4 joint publications

Mafalda Oliveira